22-Jul-10 2:00 PM CST

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

2011 Pediatric Neuro-Oncology Basic and Translational Research Conference

May 19-20, 2011

Loews Hotel, New Orleans, Louisiana

This meeting was held May 19-20, 2011, in New Orleans, Louisiana, and was a great success. Over 200 pediatric basic and translational scientists from twelve countries were in attendance to share the latest advances in the area of pediatric neuro-oncology. A full meeting recap will be posted shortly.

QUICK LINKS

OVERVIEW

The conference encouraged the sharing of ideas and results, new collaborations, and offered attendees a state-of-the-art update in the field of pediatric brain tumor research. To this end, the Scientific Program Committee created a highly informative and educational program from over 130 accepted abstracts..

The program featured popular and informative plenary sessions and informal poster sessions, as well as “Meet the Expert Sunrise Sessions”, at which attendees caught up with late breaking areas of research and controversies in the field.

This meeting was organized by the Society for Neuro-Oncology with the generous support of the Pediatric Brain Tumor Foundation.

LOCATION

The conference was held at the Loews Hotel, located only steps away from the world-famous French Quarter in New Orleans, Louisiana.

ABSTRACT SUBMISSION

Abstracts were accepted in the following categories:

Atypical Teratoid Rhabdoid Tumor (ATRT)

Basic Biology

Brainstem Tumors

Ependymoma

Immunology/Immunotherapy

Genetics/Epigenetics

Germ Cell Tumors

High Grade Gliomas

Medulloblastoma/PNETs

Pediatric Brain Tumor Models

Stem Cells
Signaling

Translational Therapeutics

SCIENTIFIC PROGRAM COMMITTEE

James Rutka, MD, PhD (Chair)

Mitchel Berger, MD

Darell Bigner, MD, PhD

David Eisenstat, MD

Jonathan Finlay, MD

Richard Gilbertson, MD, PhD
Frederick Lang, MD

Ian Pollack, MD

David Rowitch, MD, PhD

Timothy Van Meter, PhD

EDUCATIONAL OBJECTIVES

After attending the conference, participants should be able to

Perform molecular studies to characterize novel mutations important to pediatric CNS tumors (Knowledge, Competence, and Performance);
Apply innovative tumor analysis techniques to assess molecular response to therapy (Knowledge, Competence, and Performance);
Utilize novel in vitro and in vivo models of pediatric CNS tumors to test targeted therapies (Knowledge, Competence, and Performance);
Incorporate appropriate biomarker studies into clinical trial design for different pediatric CNS tumros to advance understanding of distinctive profiles that may influence therapy (Knowledge, Competence, and Performance).
Target Audience
This program is directed toward pediatric CNS tumor basic and translational scientists, and pediatric neuro-oncologists and medical oncologists.

Educational Methods
Lectures, Interactive Small Group/Breakout Sessions, Poster Sessions

Evaluation
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audiotaping, and videotaping are prohibited.